Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $27 to $26.